An In-Depth Analysis of the Investigational Compound GS-1720 and Clarification of the "GS-17" Designation

Executive Summary

This report provides a comprehensive analysis of the medication designated "GS-17," a query that encompasses multiple distinct pharmaceutical, supplemental, and investigational entities. Initial analysis reveals that the designation is ambiguous. The pill imprint "G 17" refers to at least two different commercially available medications: an over-the-counter analgesic and sleep aid combining diphenhydramine and naproxen sodium, and a prescription urinary tract analgesic, phenazopyridine hydrochloride. Furthermore, "GS 17 CAP" is the name of a multivitamin supplement produced in India. However, the most significant and data-rich subject associated with this nomenclature is the investigational compound GS-1720, a novel, long-acting oral antiretroviral for the treatment of HIV-1 infection developed by Gilead Sciences.

GS-1720 is an integrase strand transfer inhibitor (INSTI) designed for once-weekly administration, representing a potential paradigm shift from the current standard of daily oral therapy. Developed to be co-administered with GS-4182 (a prodrug of the capsid inhibitor lenacapavir), the combination regimen aims to address the unmet need for more convenient HIV treatment options, potentially improving long-term adherence and quality of life for people with HIV. Early-phase clinical trials demonstrated a promising profile for GS-1720, characterized by potent antiviral activity, a high barrier to resistance, a long pharmacokinetic half-life suitable for weekly dosing, and a favorable initial safety profile in both healthy volunteers and people with HIV.